摘要
目的探讨通心络胶囊对进展型缺血性脑卒中患者血清糖基化终产物(advanced glycation end products,AGE)、丙二醛(malondialdehyde,MDA)、超氧化物歧化酶(superoxide dismutase,SOD)、总抗氧化能力(Total antioxidant capacity,T-AOC)水平的影响。方法选取诊治的进展型缺血性脑卒中患者60例,随机分为对照组与实验组,每组30例,对照组进行常规综合治疗,实验组在常规综合治疗基础上给予通心络胶囊口服治疗,两组均治疗14 d,观察治疗前后血清AGE、MDA、SOD、T-AOC水平、神经功能缺损严重程度,并对治疗疗效进行评估。结果两组治疗前血清AGE、MDA、SOD、T-AOC水平比较差异无统计学意义(P>0.05),AGE、MDA后较治疗前均下降(P<0.05),且实验组下降幅度大于对照组(P<0.05),SOD、T-AOC治疗后较治疗前升高(P<0.05),且实验组升高幅度大于对照组(P<0.05);两组治疗前美国国立卫生院卒中量表(National Institutes of Health Stroke Scale,NIHSS)及格拉斯哥昏迷指数(Glasgow Coma Scale,GCS)评分比较差异无统计学意义(P>0.05),NIHSS评分治疗后较治疗前均下降(P<0.05),且实验组下降幅度大于对照组(P<0.05),GCS评分治疗后较治疗前升高(P<0.05),且实验组升高幅度大于对照组(P<0.05);对照组与实验组的治疗总有效率分别为73.33%(22/30)、93.33%(28/30),比较差异有统计学意义(P<0.05);Sperman相关性分析显示,进展型缺血性脑卒中患者NIHSS评分与血清AGE和MDA水平呈显著正相关(P<0.05),与SOD和T-AOC水平呈显著负相关(P<0.05),患者GCS评分与血清AGE和MDA水平呈显著负相关(P<0.05),与SOD和T-AOC水平呈显著正相关(P<0.05)。结论进展型缺血性脑卒中患者血清AGE、MDA、SOD、T-AOC水平与神经功能缺损密切相关,采用通心络胶囊治疗可有效改善患者血清AGE、MDA、SOD、T-AOC水平,促进患者神经功能的改善,提高疗效。
Objective To investigate the effect of Tongxinluo Capsule(通心络胶囊)on serum advanced glycation end products(AGE),malondialdehyde(MDA),superoxide dismutase(SOD)and total antioxidant capacity(T-AOC)of patients with progressive ischemic stroke.Methods Sixty patients of progressive ischemic stroke were randomly divided into control group and experimental group,30 cases in each group.The control group was treated with the routine comprehensive treatment and the experimental group on the basis of routine comprehensive treatment added Tongxinluo Capsule orally.Two groups were treated for 14 d.The serum levels of AGE,MDA,SOD and T-AOC and nerve function defect severity were observed before and after treatment and the curative effect was evaluated.Results There was no significant difference in serum levels of AGE,MDA,SOD or T-AOC between the two groups before treatment(P>0.05).AGE and MDA decreased after treatment compared with those before treatment(P<0.05),and the decrease amplitude of the experimental group was greater than that of the control group(P<0.05).SOD and T-AOC elevated after treatment compared with those before treatment(P<0.05),and the ascending range of the experimental group was greater than that of the control group(P<0.05).There was no significant difference in serum levels of National Institutes of Health Stroke Scale(NIHSS)or Glasgow Coma Scale(GCS)between the two groups before treatment(P>0.05).NIHSS elevated after treatment compared with that before treatment(P<0.05),and the ascending range of the experimental group was greater than that of the control group(P<0.05).GCS decreased after treatment compared with that before treatment(P<0.05),and the decrease amplitude of the experimental group was greater than that of the control group(P<0.05).The total effective rates of the control group and the experimental group were 73.33%(22/30)and 93.33%(28/30),respectively,and the difference was statistically significant(P<0.05).Sperman correlation analysis showed NIHSS score was significantly positively correlated with serum levels of AGE and MDA(P<0.05),and levels of SOD and T-AOC were significantly negatively correlated(P<0.05).GCS score was negatively correlated with serum levels of AGE and MDA(P<0.05),and positively correlated with levels of SOD and T-AOC(P<0.05).Conclusion Serum levels of AGE,MDA,SOD and T-AOC are closely related to neurological defects of patients with progressive ischemic stroke.Tongxinluo Capsule can effectively improve the serum levels of AGE,MDA,SOD and T-AOC,promote the improvement of patients'nerve function and improve the therapeutic effect.
作者
袁子薇
袁伟杰
武萌萌
杨浩雷
蒲丽丹
苏志伟
杨丽静
程丽娜
刘学飞
YUAN Ziwei;YUAN Weijie;WU Mengmeng;YANG Haolei;PU Lidan;SU Zhiwei;YANG Lijing;CHENG Lina;LIU Xuefei(Hebei Hospital of Traditional Chinese Medicine,Shijiazhuang 050000,Hebei,China;Third Hospital of Shijiazhuang,Shijiazhuang 050000,Hebei,China)
出处
《中华中医药学刊》
CAS
北大核心
2023年第5期235-238,共4页
Chinese Archives of Traditional Chinese Medicine
基金
河北省中医药管理局科研计划项目(2018013)。
关键词
通心络胶囊
进展型缺血性脑卒中
糖基化终产物
丙二醛
超氧化物歧化酶
总抗氧化能力
Tongxinluo Capsule(通心络胶囊)
progressive ischemic stroke
glycation end products
malondialdehyde
superoxide dismutas
total antioxidant capacity
